

Avacta selects potential tumour treatment for preclinical development


AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers


LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony


Abingdon Health plunges after Avacta stops selling Covid-19 test


AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests


(Sharecast News) - Avacta Group has suspended sales of its antigen lateral flow tests, causing the AIM-listed firm's share price to plummet.


Avacta shares drop as Covid tests show reduced sensitivity to Omicron


LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures